Matt Hervey
Matt is Head of Artificial Intelligence (AI) Law and a partner in the Intellectual Property (IP) team in UK. He is a leading expert on the legal and regulatory issues for AI, SEP-FRAND disputes, life sciences patent litigation, trade secrets and other IP matters.
Matt is included in Chambers & Partners as a Global Market Leader for AI, in IAM Strategy 300 (the World's Leading IP Strategists), IAM Strategy 300 Global Leaders and in IAM 1000 as "a recognised authority on AI and all SEP/FRAND issues" and for trade secrets. Legal 500 has described him as "stand out" and "absolutely superb" for patent disputes. He is recognised by JUVE Patent as a "leading individual" for patent litigation.
Matt coordinates advice on all legal and regulatory aspects of AI across all sectors, including automotive, life sciences, finance, energy, media, fashion and retail. He is General Editor of The Law of Artificial Intelligence (Sweet & Maxwell), the leading UK practitioner's book on AI and the law. He has been recognized as "one of the leading global experts in AI and IP" by the UN's World Intellectual Property Organization (WIPO) and was made a Fellow of the Royal Society of Arts in 2022 for leadership in the field of AI. He is an authority on Generative AI, advising governments, inter-governmental entities and house-hold name clients. His work includes advising on AI policies, procurement, training and fine-tuning AI models, vetting datasets, leveraging international divergences in the law and technical, practical, ethical and legal mitigations against the risks of unlawful and inappropriate outputs. His guidelines on Generative AI for WIPO have been downloaded over 23,000 times.
Matt has almost two decades of experience of SEP-FRAND litigation, including one of the largest disputes before the Patents Court of England and Wales (InterDigital v Lenovo; MIP Impact Case of the Year 2022). His SEP-FRAND cases have involved wireless and wired telecommunications standards (DECT, GSM, GPRS, EDGE, UTMS, CDMA2000, HSPA, HSPA+, LTE, LTE-Advanced, NR, G.lite, ADSL, ADSL2, ADSL2+, VDSL, VDSL2 and G.fast) and video CODEC standards (MPEG-2, MPEG-4, AVC, HEVC and VVC).
Matt's Life Sciences disputes have included monoclonal antibodies, biosimilars, toxins, medical devices and cosmetics. He successfully defended the Kennedy Trust for Rheumatology Research in the UK's first patent case on biosimilars and helped win Fujifilm Kyowa Kirin Biologics Co., Ltd the first UK "Arrow" declaration.
Matt's other cases have involved aircraft design, software (algorithmic trading, consumer share trading platforms, 3D modelling), consumer electronics (inkjet printers), location sensing and traffic analysis.